2008

Orthovita to Market Medafor's MPH® Hemostatic Technology Under the Name VITASURE™.
MINNEAPOLIS, April 27, 2008 - Medafor is pleased to announce that it has signed a non-exclusive agreement with Orthovita, Inc., Philadelphia, Penna., to distribute Medafor's patented MPH® polysaccharide hemostatic technology under the private label VITASURE™.

CryoLife Signs Exclusive Agreement to Distribute Medafor's MPH® Technology
MINNEAPOLIS, April 25, 2008 - Medafor is pleased to announce that it has signed an exclusive agreement with CryoLife, Inc., Atlanta, Ga., to distribute Medafor's patented MPH® polysaccharide hemostatic technology under the private label Hemostase MPH beginning May 1, 2008.

2007

FDA Lifts Urological Surgical Restriction for Medafor’s Arista™AH Absorbable Surgical Hemostat

MINNEAPOLIS, July 16, 2007 -- Medafor, Inc., announced today that its Arista™AH Absorbable Hemostat is now available for use in urological surgical procedures. The FDA has removed the restriction on this application of Arista AH from the device indication statement. READ FULL STORY.

2006

Medafor's FlexiTip™ Applicator Facilitates Wound Access During Surgery
MINNEAPOLIS, December 4, 2006 -- Medafor, Inc., announced today the introduction of the FlexiTip™ applicator for use with its Arista™ AH Absorbable Hemostat. Arista AH is the simple, safe and effective hemostatic powder recently approved by the FDA for most types of surgery including cardiac, orthopedic, spinal and general surgical applications. READ FULL STORY.

FDA Approves Medafor's Arista™AH Absorbable Surgical Hemostat for U.S. Operating Rooms
MINNEAPOLIS, October 3, 2006 -- Medafor, Inc., announced today that its Arista™ AH Absorbable Hemostat has received FDA approval to be marketed within the United States. Arista AH has been distributed internationally since 2002 and has compiled a remarkable record of surgical success around the world. In the U.S., this easy-to-use, efficacious and safe hemostat is indicated for most types of surgery including cardiac, orthopedic, spinal and general surgical applications. READ FULL STORY.

Medafor, Inc., Announces the Introduction of MPatcH® Vascular Closure Device to International Cardiology Markets
MINNEAPOLIS, August 15, 2006 -- Medafor, Inc., announced today that its MPatcH® vascular closure system will now be available to markets in Europe, Africa, the Middle East, Central and South America and Asia-Pacific. MPatcH® will be marketed through Medafor’s subsidiaries in Germany and France and its international distributor network. MPatcH® is distributed in the U.S. by Possis Medical, Inc. (NASDAQ:POSS). READ FULL STORY.

Possis Medical, Inc. Introduces New Solution For Endovascular Access Site Management
MINNEAPOLIS, MN.,--(BUSINESSWIRE)--May 11, 2006--Possis Medical, Inc. (NASDAQ:POSS) today announced the introduction of the SafeSeal™ Hemostasis Patch. This topical wound dressing decreases the time it takes to control bleeding from the puncture made into a blood vessel to perform an endovascular procedure. Designed to assist manual pressure and complement invasive vessel closure techniques, the SafeSeal Patch specifically targets the more than 7 million diagnostic and therapeutic procedures performed annually in the U.S. for coronary and peripheral applications. DOWNLOAD PDF.